Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-02-11 Regulatory Filings
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 11, 2019, by Eli Lilly and Company. It reports a temporary suspension of trading (a blackout period) for directors and Section 16 officers in connection with an Exchange Offer involving shares of Elanco Animal Health Incorporated. The document details the blackout restrictions, the regulatory basis (Sarbanes-Oxley Act and SEC Regulation BTR), and contact information for inquiries. It also includes a Blackout Notice as an exhibit. The content is regulatory in nature, reporting a specific event related to insider trading restrictions and employee benefit plans, rather than financial results, management changes, or capital structure updates. It does not contain financial statements or earnings data, nor is it a proxy, dividend, or merger filing. The document is a current report on Form 8-K, which is a regulatory filing used to disclose material events. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2019-02-11 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-11 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 11, 2019, by Eli Lilly and Company. It reports a temporary suspension of trading (a blackout period) for directors and Section 16 officers in connection with an Exchange Offer involving shares of Lilly common stock. The document details the blackout period, the regulatory basis (Sarbanes-Oxley Act Section 306(a) and SEC Regulation BTR), and provides contact information for inquiries. It also includes a Blackout Notice as an exhibit. The content is focused on regulatory disclosure of trading restrictions related to an employee benefit plan and an exchange offer, not on financial results, management changes, or other report types. It is a regulatory announcement about trading restrictions and blackout periods, which fits best under Regulatory Filings (RNS). The document length (7099 characters) and content confirm it is not a full financial report or earnings release but a regulatory disclosure filing.
2019-02-11 English
425 Filing
M&A Activity Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly and Company to exchange shares of Elanco Animal Health Incorporated for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, and references to a Prospectus and other related documents. The presence of Rule 425 filing and the detailed description of the exchange offer indicate this is related to merger and acquisition activity. The document is not a full annual or quarterly report, nor is it a simple announcement or proxy solicitation. It is a communication related to a takeover bid or merger transaction. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length (15,000 characters) and detailed content support a high confidence level.
2019-02-11 English
Eli Lilly and Company: Eli Lilly and Company Announces Plan for Divestiture of its Remaining Interest in Elanco Animal Health
Capital/Financing Update Classification · 95% confidence The document is a detailed press release announcing Eli Lilly and Company's plan to divest its remaining interest in Elanco Animal Health through an exchange offer. It describes the terms, conditions, timeline, and legal considerations of the exchange offer, including regulatory filings with the SEC (Form S-4 and Schedule TO). The content focuses on a capital transaction involving share exchange and divestiture, not on financial results, management changes, or legal proceedings. It is not a full financial report, earnings release, or regulatory certification. The document is lengthy (15,000 characters) and contains substantive details about the capital transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as divestitures and exchange offers.
2019-02-08 French
425 Filing
Regulatory Filings Classification · 95% confidence The document text is an election form related to an offer to exchange Eli Lilly and Company common stock fund units for Elanco stock fund units within various employee 401(k) plans. It includes instructions for participation, deadlines, and signature requirements. The text does not contain financial statements, audit information, management discussion, or earnings data. It is not a report but rather a solicitation or offer document related to a capital transaction involving stock exchange within employee plans. The document is a regulatory filing related to a corporate action but does not fit into categories like Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA) because it is specifically an offer to exchange shares within employee plans, which is a type of corporate action. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories. Confidence is high given the detailed election form nature and absence of financial or management report content.
2019-02-08 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.